BCL2 and acute myeloid leukemia: Revumenib, formerly SNDX-5613, showed safety and clinical efficacy in refractory acute leukemias, particularly in KMT2A and NPM1 mt AML, which are susceptible to apoptosis induction through BCL-2 inhibition, with added synergistic effects of menin inhibition [70,71].